

# Adjuvant Corticosteroid Treatment in Adults With Influenza

Critical Care Medicine

44, e318-e328

DOI: [10.1097/ccm.0000000000001616](https://doi.org/10.1097/ccm.0000000000001616)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical Characteristics and Treatment Experiences in 2 Serious Cases of Influenza A (H5N6) Virus Infection. <i>Journal of Clinical Case Reports</i> , 2016, 6, .	0.0	0
2	Corticosteroids for Influenza Pneumonia. <i>Critical Care Medicine</i> , 2016, 44, 1246-1248.	0.4	1
3	New aspects in the management of pneumonia. <i>Critical Care</i> , 2016, 20, 267.	2.5	23
4	Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment. <i>Clinical and Translational Immunology</i> , 2017, 6, e135.	1.7	11
5	New drug-strategies to tackle viral-host interactions for the treatment of influenza virus infections. <i>European Journal of Pharmacology</i> , 2017, 809, 178-190.	1.7	36
6	Pandemic and Avian Influenza A Viruses in Humans. <i>Clinics in Chest Medicine</i> , 2017, 38, 59-70.	0.8	47
7	A clinical approach to the threat of emerging influenza viruses in the Pacific region. <i>Respirology</i> , 2017, 22, 1300-1312.	1.3	33
8	Advances in the causes and management of community acquired pneumonia in adults. <i>BMJ: British Medical Journal</i> , 2017, 358, j2471.	2.4	135
9	Rapamycin adjuvant and exacerbation of severe influenza in an experimental mouse model. <i>Scientific Reports</i> , 2017, 7, 4136.	1.6	24
10	Avian influenza A (H7N9) virus infections in humans across five epidemics in mainland China, 2013–2017. <i>Journal of Thoracic Disease</i> , 2017, 9, 4808-4811.	0.6	8
11	Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection. <i>Journal of Infectious Diseases</i> , 2018, 217, 1708-1717.	1.9	72
12	The role of adjuvant immunomodulatory agents for treatment of severe influenza. <i>Antiviral Research</i> , 2018, 150, 202-216.	1.9	82
13	Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus. <i>Clinical Infectious Diseases</i> , 2018, 66, 1054-1060.	2.9	27
15	Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 700-701.	2.5	66
16	Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 757-767.	2.5	911
17	Muscle weakness associated with H7N9 infection: report of two cases. <i>BMC Infectious Diseases</i> , 2018, 18, 685.	1.3	0
18	Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration. <i>PLoS Pathogens</i> , 2018, 14, e1007428.	2.1	61
19	Epidemiology and Immune Pathogenesis of Viral Sepsis. <i>Frontiers in Immunology</i> , 2018, 9, 2147.	2.2	214

#	ARTICLE	IF	CITATIONS
20	Fatty Acid Metabolism is Associated With Disease Severity After H7N9 Infection. <i>EBioMedicine</i> , 2018, 33, 218-229.	2.7	32
21	Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. <i>Intensive Care Medicine</i> , 2018, 44, 1470-1482.	3.9	123
22	Clinical characteristics from co-infection with avian influenza A H7N9 and <i>Mycoplasma pneumoniae</i> : a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 77.	0.4	2
23	Application of extracorporeal membrane oxygenation in patients with severe acute respiratory distress syndrome induced by avian influenza A (H7N9) viral pneumonia: national data from the Chinese multicentre collaboration. <i>BMC Infectious Diseases</i> , 2018, 18, 23.	1.3	21
24	Severe human infection with a novel avian-origin influenza A(H7N4) virus. <i>Science Bulletin</i> , 2018, 63, 1043-1050.	4.3	19
25	Respiratory virus of severe pneumonia in South Korea: Prevalence and clinical implications. <i>PLoS ONE</i> , 2018, 13, e0198902.	1.1	16
26	Clinical and virological characteristics of human infections with H7N9 avian influenza virus in Shenzhen, China, 2013-2017. <i>Journal of Infection</i> , 2019, 79, 389-399.	1.7	3
27	Novel Avian Influenza A Virus Infections of Humans. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 907-932.	1.9	34
28	Influenza virus-related critical illness: prevention, diagnosis, treatment. <i>Critical Care</i> , 2019, 23, 214.	2.5	136
29	The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. <i>Critical Care</i> , 2019, 23, 99.	2.5	297
30	Pulmonary complications of influenza infection: a targeted narrative review. <i>Postgraduate Medicine</i> , 2019, 131, 299-308.	0.9	19
31	Severe acute respiratory syndrome and other emerging severe respiratory viral infections. <i>Respirology</i> , 2019, 24, 410-412.	1.3	1
32	Glucocorticoid treatment of suspected organizing pneumonia after H7N9 infection. <i>Medicine (United States)</i> , 2019, 98, 14.	0.4	14
33	A delicate balancing act: immunity and immunopathology in human H7N9 influenza virus infections. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 191-195.	1.3	5
34	A review on current trends in the treatment of human infection with H7N9-avian influenza A. <i>Journal of Infection and Public Health</i> , 2019, 12, 153-158.	1.9	14
35	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. <i>Clinical Infectious Diseases</i> , 2019, 68, e1-e47.	2.9	449
36	Use of glucocorticoids in the critical care setting: Science and clinical evidence. <i>Critical Care Medicine</i> , 2020, 206, 107428.		26
37	Factors Associated With Fatality Due to Avian Influenza A(H7N9) Infection in China. <i>Clinical Infectious Diseases</i> , 2020, 71, 128-132.	2.9	18

#	ARTICLE	IF	CITATIONS
38	Twenty-five years of <i>Respirology</i> : Advances in respiratory infections and tuberculosis. <i>Respirology</i> , 2020, 25, 32-34.	1.3	0
39	Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. <i>Critical Care Medicine</i> , 2020, 48, e98-e106.	0.4	139
40	Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. <i>Journal of Infectious Diseases</i> , 2020, 221, 1688-1698.	1.9	103
41	Recommended hospital preparations for future cases and outbreaks of novel influenza viruses. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 41-50.	1.0	7
42	Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 943-952.	1.8	19
43	Possible application of high-dose vitamin C in the prevention and therapy of coronavirus infection. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 256-262.	0.9	67
44	Derivation and validation of a prediction rule for mortality of patients with respiratory virus-related pneumonia (RV-p score). <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662095378.	1.0	2
45	Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: three case reports. <i>Journal of X-Ray Science and Technology</i> , 2020, 28, 885-892.	0.7	7
46	Comparison of patients hospitalized with COVID-19, H7N9 and H1N1. <i>Infectious Diseases of Poverty</i> , 2020, 9, 163.	1.5	19
47	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. <i>Arthritis and Rheumatology</i> , 2020, 72, 1791-1805.	2.9	323
48	Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2020, 7, 379-389.	0.9	12
49	Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1307.	3.8	983
50	Efficacy and Safety of Corticosteroid Treatment in Patients With COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 571156.	1.6	26
51	Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1247-1254.	0.6	18
52	Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 119-127.e4.	1.5	553
53	Clinical characteristics of Coronavirus Disease 2019 and development of a prediction model for prolonged hospital length of stay. <i>Annals of Translational Medicine</i> , 2020, 8, 443-443.	0.7	36
54	Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. <i>Cmaj</i> , 2020, 192, E756-E767.	0.9	166
55	Influenza Virus in Community-Acquired Pneumonia: Current Understanding and Knowledge Gaps. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 555-567.	0.8	3

#	ARTICLE	IF	CITATIONS
56	Association Between Cardiac Injury and Mortality in Hospitalized Patients Infected With Avian Influenza A (H7N9) Virus. <i>Critical Care Medicine</i> , 2020, 48, 451-458.	0.4	74
57	Corticosteroid administration for viral pneumonia: COVID-19 and beyond. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1171-1177.	2.8	64
58	Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 3044.	1.6	64
59	The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience. <i>Neuromodulation</i> , 2020, 23, 784-788.	0.4	57
60	A fatal paediatric case infected with reassortant avian influenza A(H5N6) virus in Eastern China. <i>Transboundary and Emerging Diseases</i> , 2020, 67, 2118.	1.3	2
61	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. <i>Journal of Autoimmunity</i> , 2020, 111, 102468.	3.0	103
62	Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. <i>Journal of Infection</i> , 2020, 81, 147-178.	1.7	241
63	Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 506-512.	2.5	73
64	High-dose but Not Low-dose Corticosteroids Potentially Delay Viral Shedding of Patients With COVID-19. <i>Clinical Infectious Diseases</i> , 2021, 72, 1297-1298.	2.9	61
65	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 112-117.	2.8	33
66	Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 543-552.	1.0	14
67	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. <i>Arthritis and Rheumatology</i> , 2021, 73, e13-e29.	2.9	314
68	Predictive value of cytokine/chemokine responses for the disease severity and management in children and adult cases with COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 2828-2837.	2.5	21
69	Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype. <i>Chest</i> , 2021, 159, 1793-1802.	0.4	51
70	Micronutrient zinc roles in adjunctive therapy for COVID-19 by enhancing patients immunoregulation and tolerance to the pathogen. <i>Reviews in Medical Microbiology</i> , 2021, Publish Ahead of Print, .	0.4	1
71	Novel Immunomodulatory Therapies for Respiratory Pathologies. , 2022, , 554-594.		5
72	Impact of Corticosteroid Administration within 7 Days of the Hospitalization for Influenza Pneumonia with Respiratory Failure: A Propensity Score Analysis Using a Nationwide Administrative Database. <i>Journal of Clinical Medicine</i> , 2021, 10, 494.	1.0	8
73	Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. <i>Respiration</i> , 2021, 100, 116-126.	1.2	99

#	ARTICLE	IF	CITATIONS
74	Multisystem inflammatory syndrome in children during the COVID-19 pandemic in Turkey: first report from the Eastern Mediterranean. <i>Clinical Rheumatology</i> , 2021, 40, 3227-3237.	1.0	29
75	Glucocorticoids Should Be Used With Caution in Patients With SARS-CoV-2. <i>Frontiers in Medicine</i> , 2021, 8, 564943.	1.2	0
76	Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?. <i>European Respiratory Review</i> , 2021, 30, 200346.	3.0	24
78	Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality. <i>Mediators of Inflammation</i> , 2021, 2021, 1-10.	1.4	15
79	The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. <i>Mycoses</i> , 2021, 64, 798-808.	1.8	149
80	Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 107.	7.1	10
81	A Review of the Evidence for Corticosteroids in COVID-19. <i>Journal of Pharmacy Practice</i> , 2022, 35, 626-637.	0.5	30
82	Cytokine/Chemokine Expression Is Closely Associated Disease Severity of Human Adenovirus Infections in Immunocompetent Adults and Predicts Disease Progression. <i>Frontiers in Immunology</i> , 2021, 12, 691879.	2.2	6
83	Emergent Pneumonia in Children. <i>Frontiers in Pediatrics</i> , 2021, 9, 676296.	0.9	3
84	Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 580989.	2.2	1
85	Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients. <i>Critical Care Research and Practice</i> , 2021, 2021, 1-10.	0.4	2
86	The authors reply. <i>Critical Care Medicine</i> , 2021, 49, e801-e802.	0.4	0
87	Monocyte-to-lymphocyte ratio is associated with 28-day mortality in patients with acute respiratory distress syndrome: a retrospective study. <i>Journal of Intensive Care</i> , 2021, 9, 49.	1.3	12
88	COVID-19, corticosteroids and public health: a reappraisal. <i>Public Health</i> , 2021, 197, 48-55.	1.4	7
89	Effects of different corticosteroid therapy on severe COVID-19 patients: a meta-analysis of randomized controlled trials. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 79-89.	1.0	7
90	Corticosteroids as adjunctive therapy in the treatment of influenza. <i>The Cochrane Library</i> , 2019, 2, CD010406.	1.5	114
93	Impact of corticosteroid treatment on clinical outcomes of influenza-associated ARDS: a nationwide multicenter study. <i>Annals of Intensive Care</i> , 2020, 10, 26.	2.2	29
94	Progress and current status of influenza researches in China. <i>Journal of Translational Internal Medicine</i> , 2019, 7, 53-58.	1.0	4

#	ARTICLE	IF	CITATIONS
95	The application of corticosteroids in COVID-19: A two-edged sword. <i>Journal of Translational Internal Medicine</i> , 2020, 8, 66-70.	1.0	5
96	Association between glucocorticoids treatment and viral clearance delay in patients with COVID-19: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2021, 21, 1063.	1.3	25
97	Specific Cytokine Profiles Predict the Severity of Influenza A Pneumonia: A Prospectively Multicenter Pilot Study. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	5
98	A literature review of drugs for the treatment of COVID-19. <i>Caribbean Medical Journal</i> , 0, , .	0.1	0
99	Application of glucocorticoids in patients with novel coronavirus infection: From bench to bedside. <i>Traditional Medicine and Modern Medicine</i> , 2020, 03, 255-268.	0.2	0
100	Avian influenza: H7N9, H5N1 and other novel strains. , 0, , 65-83.		0
101	Potential Drugs for Treating COVID-19 Infection. <i>International Journal of Infection</i> , 2020, 7, .	0.4	0
105	Sirolimus combined with oseltamivir and corticosteroid treatment for a puerpera with severe pneumonia caused by 2009 pandemic H1N1: A case report. <i>Biosafety and Health</i> , 2021, , .	1.2	0
106	Systemic corticosteroids for management of COVID-19: Saving lives or causing harm?. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110639.	1.0	12
107	Efficacité et innocuité des corticostéroïdes dans le traitement de la COVID-19 selon des données pour la COVID-19, d'autres infections aux coronavirus, l'influenza, la pneumonie extrahospitalière et le syndrome de détresse respiratoire aiguë : revue systématique et méta-analyse. <i>Cmaj</i> , 2020, 192, E1571-E1584.	0.9	1
108	Assessment of Clinical Efficacy of Dexamethasone in Patients with Moderate COVID-19. <i>Obshchaya Reanimatologiya</i> , 2022, 18, 11-16.	0.2	2
110	Discriminant models for the prediction of postponed viral shedding time and disease progression in COVID-19. <i>BMC Infectious Diseases</i> , 2022, 22, 366.	1.3	1
113	Management of pneumonia in critically ill patients. <i>BMJ</i> , The, 2021, 375, e065871.	3.0	27
115	The protective effects of a d-tetra-peptide hydrogel adjuvant vaccine against H7N9 influenza virus in mice. <i>Chinese Chemical Letters</i> , 2023, 34, 107446.	4.8	2
116	Efficacy of low-dose corticosteroids in patients with acute respiratory distress syndrome: a prospective observational study. <i>Journal of Thoracic Disease</i> , 2021, .	0.6	0
117	The Neutrophil-to-Lymphocyte Ratio is Associated with the Requirement and the Duration of Invasive Mechanical Ventilation in Acute Respiratory Distress Syndrome Patients: A Retrospective Study. <i>Canadian Respiratory Journal</i> , 2022, 2022, 1-9.	0.8	4
118	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 269-297.	0.8	2
119	Association between Glucocorticoids and Mortality in Patients with Severe Pneumonia: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-10.	0.7	3

#	ARTICLE	IF	CITATIONS
120	Respiratory viruses: their importance and lessons learned from COVID-19. <i>European Respiratory Review</i> , 2022, 31, 220051.	3.0	13
121	A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries. <i>Journal of Global Health</i> , 0, 12, .	1.2	5
122	Analysis of risk factors of fungal superinfections in viral pneumonia patients: A systematic review and meta-analysis. <i>Immunity, Inflammation and Disease</i> , 2023, 11, .	1.3	1
123	Outcomes of corticosteroid treatment in critical Ill adult patients with respiratory viruses-related community acquired pneumonia – a propensity-matched case control study. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, , .	1.5	0
124	Clinical and pharmacological factors associated with mortality in patients with COVID-19 in a high complexity hospital in Manaus: A retrospective study. <i>PLoS ONE</i> , 2023, 18, e0280891.	1.1	1